You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cost Effectiveness of Herpes Zoster Vaccine in Canada
|
|---|---|
| Published in |
PharmacoEconomics, September 2012
|
| DOI | 10.2165/11314010-000000000-00000 |
| Pubmed ID | |
| Authors |
Mehdi Najafzadeh, Carlo A. Marra, Eleni Galanis, David M. Patrick |
| Abstract |
Herpes zoster (HZ), or shingles, results from reactivation of latent varicella zoster virus in the sensory ganglia of adults, and results in significant morbidity in the elderly, including the development of post-herpetic neuralgia (PHN). The lifetime risk of HZ is about 20-30% and the incidence increases with age. The protective effect of the HZ vaccine has been shown in a large clinical trial; however, the effectiveness of the vaccine decreased with age of vaccination. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 50% |
| United States | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Scientists | 1 | 25% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 74 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 20% |
| Student > Master | 14 | 18% |
| Student > Ph. D. Student | 9 | 12% |
| Student > Doctoral Student | 5 | 7% |
| Student > Bachelor | 4 | 5% |
| Other | 15 | 20% |
| Unknown | 14 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 36% |
| Economics, Econometrics and Finance | 8 | 11% |
| Social Sciences | 5 | 7% |
| Nursing and Health Professions | 4 | 5% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 11 | 14% |
| Unknown | 18 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 August 2018.
All research outputs
#6,373,276
of 25,373,627 outputs
Outputs from PharmacoEconomics
#739
of 1,991 outputs
Outputs of similar age
#46,287
of 189,082 outputs
Outputs of similar age from PharmacoEconomics
#204
of 548 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,991 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,082 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 548 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.